☆ 4.7 Article

Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial

CLINICAL MICROBIOLOGY AND INFECTION (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Immunology

AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial

Andrey A. Ivashchenko et al.

Summary: In May 2020, AVIFAVIR, an RNA polymerase inhibitor, was granted fast-track marketing authorization by the Russian Ministry of Health for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR demonstrated a 62.5% viral clearance rate within 4 days for SARS-CoV-2 patients and was shown to be safe and well-tolerated.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Medicine, General & Internal

Repurposed Antiviral Drugs for Covid-19-Interim WHO Solidarity Trial Results

Summary: The authors of the study reported the interim results of using four repurposed antiviral drugs (remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a) in hospitalized COVID-19 patients. The study showed that these drug regimens had little or no effect on overall mortality, initiation of ventilation, and duration of hospital stay.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Infectious Diseases

Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial

Zarir F. Udwadia et al.

Summary: The study aimed to assess the efficacy and safety of favipiravir in adults with mild-to-moderate COVID-19. Results showed a significant improvement in time to clinical cure with favipiravir, although there was no statistically significant difference in viral shedding cessation time.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Medicine, General & Internal

Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis

Ahmad Alamer et al.

Summary: The study found that Favipiravir was associated with clinical benefits in COVID-19 patients, including accelerated discharge rate and less progression to mechanical ventilation. However, no overall mortality benefits were seen across the severity spectrum. Age was identified as an independent risk factor for mortality in mechanically ventilated patients.

CURRENT MEDICAL RESEARCH AND OPINION (2021)

添加到收藏夹

Article Medicine, General & Internal

Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19 The TOGETHER Randomized Clinical Trial

Gilmar Reis et al.

Summary: This randomized clinical trial did not find any significant benefit in reducing COVID-19-associated hospitalization or other secondary clinical outcomes with hydroxychloroquine or lopinavir-ritonavir among high-risk outpatients.

JAMA NETWORK OPEN (2021)

添加到收藏夹

Review Infectious Diseases

Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis

Toshie Manabe et al.

Summary: The study suggests that favipiravir shows promising efficacy in treating patients with COVID-19, inducing viral clearance within 7 days and contributing to clinical improvement within 14 days. The drug is especially effective for patients with mild-to-moderate illness. However, additional well-designed studies are needed to determine the optimal dosage and duration of treatment.

BMC INFECTIOUS DISEASES (2021)

添加到收藏夹

Review Infectious Diseases

Effectiveness of favipiravir in COVID-19: a live systematic review

Batu Ozlusen et al.

Summary: This study found no significant difference in fatality rate and mechanical ventilation requirement between Favipiravir treatment and the standard of care in moderate to severe COVID-19 patients.

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2021)

添加到收藏夹

Review Multidisciplinary Sciences

The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials

Soheil Hassanipour et al.

Summary: The meta-analysis of Favipiravir in the treatment of COVID-19 showed significant clinical improvement in the Favipiravir group compared to the control group after seven days of hospitalization. However, there was no significant difference in viral clearance and oxygen therapy requirement between the two groups. The mortality rate was approximately 30% lower in the Favipiravir group, but this finding was not statistically significant.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial

Chang Chen et al.

Summary: This study compared the efficacy and safety of favipiravir and umifenovir (Arbidol) in treating COVID-19 patients. Although favipiravir showed a shorter duration for relief of fever and cough, it did not significantly improve the clinical recovery rate at day 7 compared to Arbidol. The adverse effects associated with favipiravir were mild and manageable.

FRONTIERS IN PHARMACOLOGY (2021)

添加到收藏夹

Article Infectious Diseases

Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial

Masaharu Shinkai et al.

Summary: The study found that favipiravir may be an option for treating moderate COVID-19 pneumonia, with better effects in patients with obesity or coexisting conditions. However, the risk of adverse events, including hyperuricemia, should be carefully considered when using favipiravir.

INFECTIOUS DISEASES AND THERAPY (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Zunyou Wu et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Favipiravir, an anti-influenza drug against life-threatening RNA virus infections

Kimiyasu Shiraki et al.

PHARMACOLOGY & THERAPEUTICS (2020)

添加到收藏夹

Article Immunology

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Xueting Yao et al.

CLINICAL INFECTIOUS DISEASES (2020)

添加到收藏夹

Article Medicine, Research & Experimental

SARS-CoV-2 RNA polymerase as target for antiviral therapy

Luigi Buonaguro et al.

JOURNAL OF TRANSLATIONAL MEDICINE (2020)

添加到收藏夹

Article Microbiology

A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19

Yohei Doi et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)

添加到收藏夹

Editorial Material Infectious Diseases

Early Treatment of COVID-19 Disease: A Missed Opportunity

Jamie I. Forrest et al.

INFECTIOUS DISEASES AND THERAPY (2020)

添加到收藏夹

Letter Medicine, Research & Experimental

A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial

Mohammad Bosaeed et al.

TRIALS (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Favipiravir as a potential countermeasure against neglected and emerging RNA viruses

Leen Delang et al.

ANTIVIRAL RESEARCH (2018)

添加到收藏夹

Review Multidisciplinary Sciences

Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase

Yousuke Furuta et al.

PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES (2017)

添加到收藏夹

Article Immunology

1341The benefit of early influenza antiviral treatment of pregnant women hospitalized with laboratory-confirmed influenza

Ikwo Oboho et al.

Open Forum Infectious Diseases (2017)

添加到收藏夹

Article Virology

T-705 (Favipiravir) Induces Lethal Mutagenesis in Influenza A H1N1 Viruses In Vitro

Tatiana Baranovich et al.

JOURNAL OF VIROLOGY (2013)

添加到收藏夹

Article Infectious Diseases

Early versus late oseltamivir treatment in severely ill patients with 2009 pandemic influenza A (H1N1): speed is life

Anand Kumar

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.